🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-526530-13-00
Authorised Phase II

"Evaluation of the impact of the dose of heparin on the occurrence of DWI ischemic lesions after embolization of unruptured intracranial aneurysm" "HARMONI"

2026-526530-13-00 · tracked via the Priya Life Science EU tracker
Sponsor
Centre Hospitalier Universitaire De Bordeaux
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Nervous System Diseases
Decision date
07/09/2026
Enrollment target
124
Sites
France

Condition studied

Intracranial aneurysms

Investigational medicinal product(s)

HEPARINE SODIQUE PANPHARMA 5 000 UI/mlsolution injectable (I.V.)PROTAMINE SULFATEACETYLSALICYLIC ACIDTICAGRELOR

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

Percentage of the presence of at least one recent ischemic lesion visible on diffusion-weighted MRI at 24 hours postoperatively, in each treatment arm.

Endpoint detail

Rate of intraoperative angiographic thromboembolic events in each arm, Proportion of subjects with more than 5 punctate ischemic lésions, or a territorial ischemic stroke visible on diffusion-weighted MRI at 24 hours postoperatively, in each arm., Mean volume of recent ischemic lesions on diffusion-weighted MRI at 24 hours postoperatively, in each arm, Rate of subjects with symptomatic ischemic stroke within 24 hours postoperatively , in each arm., NIHSS score at 24 hours postoperatively in each arm, Rate of major hemorrhagic events (intraoperative or within the first 24 hours postoperatively) in each arm, Rate of minor hemorrhagic events (intraoperative or within the first 24 hours postoperatively), Proportion of subjects who experienced any ischemic event within 24 hours after the procedure.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526530-13-00 on CTIS ↗ ← All trials in the EU